Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study is a research paper published in Journal of Clinical Oncology (2024). On theSindex it has a DataRank of 0.644. It has been cited 20 times, with 20 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0.187
From 12 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 20 citers.
NCI NIH HHS
Grant: UG1 CA233290
NCI NIH HHS
Grant: UG1 CA233339
NCI NIH HHS
Grant: U10 CA180822
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: U10 CA180868
MeSH Terms